A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
A phase 3 trial of Lerociclib run by Genor Biopharma Co., Ltd., now recruiting.
Overview
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer is a phase 3 interventional study registered as NCT05851014 by Genor Biopharma Co., Ltd., with 350 participants planned, started 2022-01-14. Conditions listed: Breast Cancer. No results are recorded here; the registry entry is the source.
Setting
A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of GB491 in Combination With Letrozole in Subjects With HR Positive and HER2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received Systemic Therapy in This Disease Setting
Phase
Phase 3
Sponsor
Genor Biopharma Co., Ltd.
Registry
Enrolled
350